| http://www.w3.org/ns/prov#value | - In the second quarter of 2011, GTx plans to initiate another trial evaluating Capesaris, a possible alternative to androgen deprivation therapy, the standard care for men with advanced prostate cancer, which can result in side effects such as bone loss and hot flashes.
|
